跳至主要内容
临床试验/NCT00399594
NCT00399594已完成2 期

Investigating Non-response to Cardiac Resynchronization: Evaluation of Methods to Eliminate Non-response & Target Appropriate Lead Location (INCREMENTAL).

University of Calgary5 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2011年3月最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
96
试验地点
5
主要终点
Change in end systolic volume plus reduction in symptoms

研究概览

简要总结

Identifying & optimizing strategies to reduce the burden of heart failure is vital. Despite advances in pharmacotherapy, patients with heart failure are at high risk for death & hospitalization. Cardiac resynchronization therapy (CRT) synchronizes ventricular mechanical activity, improves cardiac output & reduces HF symptoms. However, ~50% of patients do not clearly respond to CRT. Sub-optimal placement of the LV pacing lead appears to be an important reason for non-response.

This study will assess whether targeted LV lead placement will result in an increased probability of CRT response at 52 weeks vs. usual (lateral wall) lead placement.

详细描述

Background. Identifying & optimizing strategies to reduce the burden of heart failure (HF) is vital. Despite advances in pharmacotherapy, patients with HF are at high risk for death & hospitalization. Over 25% of patients with systolic HF have dyssynchronous ventricular contraction that results in paradoxical septal motion, further impairing left ventricular (LV) function & HF progression. Cardiac resynchronization therapy (CRT) synchronizes ventricular mechanical activity, improves cardiac output & reduces HF symptoms. However, ~50% of patients do not clearly respond to CRT. Sub-optimal placement of the LV pacing lead appears to be an important reason for non-response.

Screening. Mechanical synchrony is vitally important in optimizing CRT response. Patients will be pre-screened with echocardiograms (echo) & CRT provided to only those with dyssynchrony. The predicted rate of CRT response in patients pre-screened for dyssynchrony is estimated at 65%.

CRT response. The combined use of a valid & simple measure of functional capacity with a reproducible measure of LV volume is optimal in identifying CRT responders. These outcomes will be assessed using the Specific Activity Scale & radionuclide angiography (RNA), respectively.

Primary hypothesis. Targeted LV lead placement will result in an increased probability of CRT response at 52 weeks vs. usual (lateral wall) lead placement. CRT response will be defined as ≥ 10% relative reduction in LV end systolic volume & ≥ 1 Specific Activity Scale class improvement.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • LV EF ≤ 0.40 measured within 3 months of enrollment,
  • SAS class 3 or 4 symptoms indicative of moderate to severe functional capacity limitation due to heart failure within 1 month of enrollment.
  • Confirmed dyssynchrony on screening echo (1.1.9), &
  • On stable doses of ACE inhibitor or angiotensin II blocker & a beta-blocker for ≥ 2 months unless medically contra-indicated.
  • Controlled heart rate if in permanent AF (resting <70 & maximal <120).

排除标准

  • Unable or unwilling to provide informed consent,
  • Medical condition other than heart failure likely to cause death < 1 year,
  • Cardiac transplant planned within 6 months,
  • Known contra-indication to transvenous CRT device implant (e.g., active sepsis, artificial tricuspid valve, known vascular occlusion that will prevent delivery of leads transvenously),
  • Clinically significant myocardial infarction within last 2 months, or
  • Coronary bypass graft surgery ≤ 2 months or coronary angioplasty ≤ 1 month

研究组 & 干预措施

A

Experimental

Targeted LV lead placement

干预措施: A (Procedure)

B

Active Comparator

Usual LV lead placement

干预措施: B (Procedure)

结局指标

主要结局

Change in end systolic volume plus reduction in symptoms

时间窗: over 12 months

次要结局

  • Specific Activity Scale score.(Change over 12 months)
  • LV volumes.(Change over 12 months)
  • N-terminal pro-B-type natriuretic peptide.(Change over 12 months)
  • Hospitalization(Study duration)
  • New York Heart Association class.(Change over 12 months)
  • Mortality(Study duration)
  • Minnesota Living with Heart Failure score.(Change over 12 months)
  • Short form thirty six score.(Change over 12 months)
  • Six minute walk distance.(Change over 12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Derek Exner

Professor and Canada Research Chair in Cardiovascular Clinical Trials

University of Calgary

研究点 (5)

Loading locations...

相似试验